BICYCLE THERAPEUTICS PLC-ADR (BCYC) Stock Analyst Ratings
USA - NASDAQ:BCYC - US0887861088 - ADR
8.12 USD
+0.24 (+3.05%)
8.12 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 82% to BCYC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.91. This target is 206.71% above the current price.
BCYC was analyzed by 20 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about BCYC.
In the previous month the buy percentage consensus was at a similar level.
BCYC was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-12 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-08-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-07-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-06 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-02 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-05-02 | Needham | Reiterate | Buy -> Buy |
| 2025-05-02 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-02 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2025-05-01 | Barclays | Maintains | Overweight -> Overweight |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
| 2025-03-11 | Needham | Reiterate | Buy -> Buy |
| 2025-02-26 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-26 | Needham | Reiterate | Buy -> Buy |
| 2025-02-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | Stephens & Co. | Reiterate | Equal-Weight -> Equal-Weight |
| 2025-01-13 | Needham | Reiterate | Buy -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-12-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-12-13 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2024-11-08 | Stephens & Co. | Initiate | Equal-Weight |
| 2024-11-01 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | Needham | Reiterate | Buy -> Buy |
| 2024-10-24 | Needham | Reiterate | Buy -> Buy |
| 2024-10-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | Needham | Reiterate | Buy -> Buy |
| 2024-09-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
BICYCLE THERAPEUTICS PLC-ADR / BCYC FAQ
What is the price target for BCYC stock?
20 analysts have analysed BCYC and the average price target is 24.91 USD. This implies a price increase of 206.71% is expected in the next year compared to the current price of 8.12.
What is the consensus rating for BCYC stock?
The consensus rating for BICYCLE THERAPEUTICS PLC-ADR (BCYC) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.